Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tideglusib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 25,173Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AMO Outlines AMO-02 Myotonic Dystrophy Development Post-FDA Meet
    AMO Outlines AMO-02 Myotonic Dystrophy Development Post-FDA Meet

    02 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amo-pharma-completes-meeting-with-us-fda-and-outlines-plans-to-advance-clinical-development-of-amo-02-tideglusib-in-treatment-of-myotonic-dystrophy-302133891.html

    PR NEWSWIRE
    02 May 2024
    Share Share
    AMO Pharma Announces Collaboration with Population Health Research Institute
    AMO Pharma Announces Collaboration with Population Health Research Institute

    15 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amo-pharma-announces-collaboration-with-population-health-research-institute-to-advance-proof-of-concept-clinical-trial-to-assess-efficacy-of-tideglusib-in-treatment-of-arrhythmogenic-cardiomyopathy-302062622.html

    PR NEWSWIRE
    15 Feb 2024
    Share Share
    AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in CMD1
    AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in CMD1

    22 Dec 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/amo-pharma-announces-expansion-of-pivotal-reach-cdm-study-in-congenital-myotonic-dystrophy-301449576.html

    PRNEWSWIRE
    22 Dec 2021
    Share Share
    AMO Pharma Announces First Patient Enrolled In REACH-CDM
    AMO Pharma Announces First Patient Enrolled In REACH-CDM

    30 Sep 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/amo-pharma-announces-first-patient-enrolled-in-reach-cdm-x-12-month-open-label-study-301388304.html

    PRNEWSWIRE
    30 Sep 2021
    Share Share
    AMO Pharma Reports +ve Data from Investigator-Led TIDE Study of AMO-02 in ASD
    AMO Pharma Reports +ve Data from Investigator-Led TIDE Study of AMO-02 in ASD

    29 Oct 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amo-pharma-reports-positive-data-from-investigator-led-tide-study-of-amo-02-in-autism-spectrum-disorder-300739432.html

    PR NEWSWIRE
    29 Oct 2018
    Share Share